Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/correlation-of-hepatitis-b-virus-load-with-loss-of-e-antigen-and-pAEdza9Wuv
References (23)
-
B. Song, D. Suh, H. Lee, Y. Chung, Y. Lee (2000)
Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in KoreaHepatology, 32
-
L. Perrin, A. Telenti (1998)
HIV treatment failure: testing for HIV resistance in clinical practice.Science, 280 5371
-
D. Lau, M. Khokhar, E. Doo, M. Ghany, D. Herion, Y. Park, D. Kleiner, P. Schmid, Lynn Condreay, J. Gauthier, M. Kuhns, T. Liang, J. Hoofnagle (2000)
Long‐term therapy of chronic hepatitis B with lamivudineHepatology, 32
-
E. Puchhammer-Stöckl, C. Mandl, J. Kletzmayr, H. Holzmann, A. Hofmann, S. Aberle, F. Heinz, B. Watschinger, H. Hofmann (2000)
Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy.The Journal of infectious diseases, 181 6
-
(1998)
the Asia Hepatitis Lamivudine Study -
B. Zöllner, H. Feucht, L. Weitner, A. Adam, R. Laufs (1999)
Drug-resistant genotyping in HIV-1 therapyThe Lancet, 354
-
K. Heermann, W. Gerlich, M. Chudy, S. Schaefer, R. Thomssen (1999)
Quantitative Detection of Hepatitis B Virus DNA in Two International Reference Plasma PreparationsJournal of Clinical Microbiology, 37
-
K. Loeb, K. Jerome, J. Goddard, Meei-Li Huang, Anne Cent, L. Corey (2000)
High‐Throughput Quantitative Analysis of Hepatitis B Virus DNA in Serum Using the TaqMan Fluorogenic Detection SystemHepatology, 32
-
S. Kubo, K. Hirohashi, Hiromu Tanaka, T. Tsukamoto, T. Shuto, Takatsugu Yamamoto, T. Ikebe, K. Wakasa, S. Nishiguchi, H. Kinoshita (2000)
Effect of viral status on recurrence after liver resection for patients with hepatitis B virus–related hepatocellular carcinomaCancer, 88
-
C. Boni, A. Penna, G. Ogg, A. Bertoletti, M. Pilli, C. Cavallo, A. Cavalli, S. Urbani, R. Boehme, R. Panebianco, F. Fiaccadori, C. Ferrari (2001)
Lamivudine treatment can overcome cytotoxic T‐cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapyHepatology, 33
-
J. Dienstag, E. Schiff, M. Mitchell, D. Casey, N. Gitlin, T. Lissoos, L. Gelb, Lynn Condreay, L. Crowther, M. Rubin, N. Brown (1999)
Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapyHepatology, 30
-
K. Chayama, Yoshiyuki Suzuki, M. Kobayashi, Mizuho Kobayashi, A. Tsubota, M. Hashimoto, Y. Miyano, H. Koike, M. Kobayashi, I. Koida, Y. Arase, S. Saitoh, N. Murashima, K. Ikeda, H. Kumada (1998)
Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapyHepatology, 27
-
(1998)
DLJ, Brown N, for the lamivudine clinical trial group, Condreay LD -
D. Mutimer, D. Pillay, E. Dragon, Howard Tang, M. Ahmed, Katharina O'Donnell, J. Shaw, N. Burroughs, David Rand, P. Cane, Brian Martin, Sandy Buchan, E. Boxall, S. Barmat, K. Gutekunst, P. Mcmaster, E. Elias (1999)
High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation.Journal of hepatology, 30 4
-
J. Dienstag, E. Schiff, T. Wright, R. Perrillo, H. Hann, Z. Goodman, L. Crowther, Lynn Condreay, M. Woessner, M. Rubin, N. Brown (1999)
Lamivudine as initial treatment for chronic hepatitis B in the United States.The New England journal of medicine, 341 17
-
C. Boni, A. Bertoletti, A. Penna, A. Cavalli, M. Pilli, S. Urbani, P. Scognamiglio, R. Boehme, R. Panebianco, F. Fiaccadori, C. Ferrari (1998)
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.The Journal of clinical investigation, 102 5
-
Ching‐lung Lai, R. Chien, N. Leung, Ting Chang, R. Guan, D. Tai, K. Ng, P. Wu, J. Dent, J. Barber, S. Stephenson, D. Gray (1998)
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.The New England journal of medicine, 339 2
-
S. Pas, E. Fries, R. Man, A. Osterhaus, H. Niesters (2000)
Development of a Quantitative Real-Time Detection Assay for Hepatitis B Virus DNA and Comparison with Two Commercial AssaysJournal of Clinical Microbiology, 38
-
Ally, S. L., Tephenson (2000)
A ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B -
(1999)
High pretreatment serum hepatitis B virus titre predicts failure -
S. Locarnini, C. Birch (1999)
Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients.Journal of hepatology, 30 3
-
HBV DNA During Lamivudine Therapy -
M. Allen, M. Deslauriers, C. Andrews, G. Tipples, K. Walters, D. Tyrrell, N. Brown, Lynn Condreay (1998)
Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 27
- Publisher
- Wiley
- Copyright
- Copyright © 2001 Wiley Subscription Services
- ISSN
- 0146-6615
- eISSN
- 1096-9071
- DOI
- 10.1002/jmv.2087
- Publisher site
- See Article on Publisher Site
Abstract
It remains unclear whether sequential assessment of hepatitis B virus (HBV) load during lamivudine therapy can predict the loss of hepatitis B e antigen or emergence of drug‐resistant variants. Therefore, a longitudinal study was carried out in 28 consecutive patients with chronic hepatitis B who started lamivudine therapy for a median of 12 months (range, 6–31). HBV DNA copy numbers were determined at 3‐month intervals. From month 6 onward, HBV viral load below the detection limit of the PCR was predictive of the loss of envelope antigen (P = 0.043). Continuously detectable HBV DNA during the first 12 months of treatment indicated emergence of drug‐resistant variants (P = 0.034). These data suggest that the goal of lamivudine therapy should be complete suppression of serum HBV DNA. J. Med. Virol. 65:659–663, 2001. © 2001 Wiley‐Liss, Inc.
Journal
Journal of Medical Virology – Wiley
Published: Jan 1, 2001
Keywords: ; ; ; ;